Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
PGC-1α pathway dysregulation disrupts myofiber specification in a mouse model of SBMA
Curtis J. Kuo, Laura B. Chopp, Zhigang Yu, Luhan Ni, Hien T. Zhao, Janghoo Lim, Andrew P. Lieberman
Curtis J. Kuo, Laura B. Chopp, Zhigang Yu, Luhan Ni, Hien T. Zhao, Janghoo Lim, Andrew P. Lieberman
View: Text | PDF
Research Article Muscle biology Neuroscience

PGC-1α pathway dysregulation disrupts myofiber specification in a mouse model of SBMA

  • Text
  • PDF
Abstract

Skeletal muscle pathology is a critical but poorly understood contributor to neuromuscular degeneration in spinal and bulbar muscular atrophy (SBMA), a CAG/polyglutamine (polyQ) expansion disorder caused by mutation in the androgen receptor (AR). Using a gene-targeted SBMA mouse model, we applied single-nucleus RNA sequencing to identify a disease-specific population of skeletal muscle myonuclei that replaced normal myonuclear subtypes. This transition was associated with dysregulation of the pathway governed by PGC-1α, a central regulator of myofiber specification and metabolic identity. PGC-1α dysfunction in SBMA muscle was age, hormone, and polyQ length dependent and was partially rescued by subcutaneous delivery of AR-targeted antisense oligonucleotides. Integrated ChIP-seq and RNA-seq analyses revealed that aberrant PGC-1α activity promoted the expression of a distinct set of myofiber specification genes while downregulating those that define healthy Type IIb and Type IIx myonuclei. We propose a model in which this dysfunction arose downstream of polyQ-mediated sequestration of PGC-1α cofactors MEF2, CREB, and CBP, leading to transcriptional reprogramming and cellular dysfunction. These findings implicated PGC-1α dysregulation as a key event linking AR polyQ expansion to skeletal muscle degeneration and suggested a shared mechanism for polyQ-mediated muscle pathology across related neurodegenerative diseases.

Authors

Curtis J. Kuo, Laura B. Chopp, Zhigang Yu, Luhan Ni, Hien T. Zhao, Janghoo Lim, Andrew P. Lieberman

×

Figure 3

Rescue of myonuclei cluster–defining genes by AR-targeted ASO.

Options: View larger image (or click on image) Download as PowerPoint
Rescue of myonuclei cluster–defining genes by AR-targeted ASO.
AR113Q or...
AR113Q or WT males were administered AR-targeted ASO (25 mg/kg body weight) or vehicle subcutaneously, once per week, from 26 to 52 weeks. (A–D) Heatmaps showing log2(fold change) of the top 25 cluster-defining genes for each of the indicated myonuclei groups, as assessed by bulk RNA-seq of TA from independent cohorts of 52-week male mice (n = 4/group). Comparisons were between vehicle-treated AR113Q and vehicle-treated WT (left column), and between ASO-treated AR113Q and vehicle-treated AR113Q (right column). Color scales, ranging from red (positive) to blue (negative), were set by mapping the log2(FC) with the largest absolute value for each set of 25 genes to the appropriate extreme (pure blue or pure red) and setting the inverse of that value to the other color, such that log2(FC) = 0 is exactly in the middle as pure white. (E–L) Overlay of all cluster-defining genes for the indicated cluster, color coded as in Figure 1C, among the volcano plot of all genes. Dotted lines indicate thresholds of Padj < 0.05, |log2(FC)| > 0.5849. (E–H) Vehicle-treated AR113Q vs. vehicle-treated WT. (I–L) ASO-treated AR113Q vs. vehicle-treated AR113Q.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts